Most patients with alopecia areata who had hair regrowth with baricitinib and discontinued maintenance therapy experienced a relapse of hair loss.

Incyte Corp's new patent details innovative methods for synthesizing baricitinib, a key rheumatoid arthritis treatment, enhancing pharmaceutical manufacturing processes.

The observed lower mortality with remdesivir plus dexamethasone in patients on IMV/ECMO "further supports the growing ...

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful ...

On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm ...

With alopecia areata in the headlines, Clinical Trials Arena looks at a potential shake-up in its drug options and an ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

Forty percent also said they took immunosuppressants, including cyclosporine, methotrexate and azathioprine, Chu said, adding that about 15 percent of them also took small molecule targeted drugs, ...

The first, called nirmatrelvir, blocks the activity of an enzyme the COVID-19 virus needs to copy itself, also called repl ...

A 40-year-old man presented to the emergency department with a 5-day history of fevers, sore throat, fatigue, subjective ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...